🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

AbbVie Inc (ABBV)

Mexico
Currency in MXN
3,540.13
0.00(0.00%)
Delayed Data
ABBV Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
Fair Value
Day's Range
3,540.133,540.13
52 wk Range
2,612.904,080.50
Key Statistics
Edit
Bid/Ask
3,520.00 / 3,550.00
Prev. Close
3,540.13
Open
3,540.13
Day's Range
3,540.13-3,540.13
52 wk Range
2,612.9-4,080.5
Volume
-
Average Volume (3m)
844
1-Year Change
34.7%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABBV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
202.67
Upside
+15.40%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

AbbVie Inc Company Profile

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Employees
50000

Compare ABBV to Peers and Sector

Metrics to compare
ABBV
Peers
Sector
Relationship
P/E Ratio
61.4x−1.7x−0.7x
PEG Ratio
−2.860.030.00
Price/Book
51.7x5.1x2.6x
Price / LTM Sales
5.6x10.6x3.2x
Upside (Analyst Target)
-427.8%47.1%
Fair Value Upside
Unlock14.6%7.3%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.87
Dividend Yield
3.70%
Industry Median 2.52%
Annualised payout
132.3349
Paid quarterly
5-Years Growth
-
Growth Streak

FAQ

What Is the AbbVie (ABBV) Stock Price Today?

The AbbVie stock price today is 3,540.13.

What Stock Exchange Does AbbVie Trade On?

AbbVie is listed and trades on the Mexico stock exchange.

What Is the Stock Symbol for AbbVie?

The stock symbol for AbbVie is "ABBV."

Does AbbVie Pay Dividends? What’s The Current Dividend Yield?

The AbbVie Inc dividend yield is 3.74%.

What Is the AbbVie Market Cap?

As of today, AbbVie market cap is 6.25T.

What is AbbVie Earnings Per Share?

The AbbVie EPS is 2.87.

From a Technical Analysis Perspective, Is ABBV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.